Bank Pictet & Cie (Europe)’s Apellis Pharmaceuticals APLS Stock Holding History

Bank Pictet & Cie (Europe)’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6,825	Closed	-$260K	–	274
2023 Q3	$260K	Sell	6,825 -94	-1%	-$4.13K	0.01%	230
2023 Q2	$630K	Sell	6,919 -422	-6%	-$36.4K	0.02%	163
2023 Q1	$484K	Buy	7,341 +79	+1%	+$4.56K	0.02%	130
2022 Q4	$376K	Sell	7,262 -35	-0.5%	-$1.86K	0.02%	134
2022 Q3	$498K	Hold	7,297	–	–	0.02%	120
2022 Q2	$330K	Sell	7,297 -1,772	-20%	-$80.8K	0.02%	131
2022 Q1	$461K	Buy	9,069 +2,734	+43%	+$121K	0.02%	129
2021 Q4	$300K	Buy	+6,335	New	+$249K	0.01%	147
2021 Q3	–	Sell	-9,041	Closed	-$571K	–	170
2021 Q2	$571K	Buy	9,041 +1,160	+15%	+$59.9K	0.02%	132
2021 Q1	$338K	Buy	+7,881	New	+$373K	0.01%	148

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Bank Pictet & Cie (Europe)'s APLS Position: Q4 2023 in Review

Bank Pictet & Cie (Europe) sold out of Apellis Pharmaceuticals (APLS) in Q4 2023, closing a stake of 6,825 shares — an estimated $260K sold.

Bank Pictet & Cie (Europe) first reported a position in APLS in Q1 2021 and held it in 10 quarters. The position peaked at $630K in Q2 2023. 283 funds tracked by Wall St. Rank hold APLS as of Q4 2023.

Bank Pictet & Cie (Europe) reported no remaining Apellis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Bank Pictet & Cie (Europe) sold 6,825 Apellis Pharmaceuticals shares in Q4 2023, an estimated $260K.
Bank Pictet & Cie (Europe) first reported a position in Apellis Pharmaceuticals in Q1 2021 and held it in 10 quarters.
Bank Pictet & Cie (Europe)'s Apellis Pharmaceuticals position peaked at $630K in Q2 2023.
283 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2023.

Based on Bank Pictet & Cie (Europe)'s 13F filing for Q4 2023, filed 9 Feb 2024.